Cadila Healthcare on Friday said that the USFDA inspected the company’s formulations manufacturing facility located at Moraiya, Ahmedabad, from April 22 to May 3. The inspection concluded with 14 observations. There were no repeat observations or Data Integrity-related observations, the company said, and added that it is confident of addressing these observations and responding to the USFDA at the earliest. Shareholders will closely monitor the developments.